{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:28:25Z","timestamp":1790742505606,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MSD"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bjid.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T17:17:13Z","timestamp":1560532633000},"page":"191-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-2046","authenticated-orcid":false,"given":"Jo\u00e3o Paulo","family":"Telles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Cieslinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Francisco","family":"Tuon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2019.05.006_bib0005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bjid.2019.05.006_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijantimicag.2011.09.030","article-title":"Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods","volume":"39","author":"Stefani","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2019.05.006_bib0015","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0924-8579(09)70551-5","article-title":"MRSA burden and interventions","volume":"34 Suppl 3","author":"Liebowitz","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2019.05.006_bib0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jac\/dkp245","article-title":"Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin","volume":"64","author":"Nathwani","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1139\/cjm-2015-0855","article-title":"Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative staphylococcus biofilm and bacterial viability within biofilm: an in vitro biofilm model","volume":"62","author":"Ozturk","year":"2016","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.bjid.2019.05.006_bib0035","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1128\/AAC.00735-16","article-title":"New insight into daptomycin bioavailability and localization in Staphylococcus aureus biofilms by dynamic fluorescence imaging","volume":"60","author":"Boudjemaa","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/1469-0691.12003","article-title":"Antimicrobial treatment concepts for orthopaedic device-related infection","volume":"18","author":"Sendi","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2019.05.006_bib0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14656561003598893","article-title":"Daptomycin: pharmacology and clinical use","volume":"11","author":"Kosmidis","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12879-016-1590-3","article-title":"A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin","volume":"16","author":"Hermsen","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Seaton","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.bjid.2019.05.006_bib0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-015-2515-6","article-title":"Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry","volume":"35","author":"Malizos","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12325-015-0220-6","article-title":"Daptomycin in the clinical setting: 8-year experience with Gram-positive bacterial infections from the EU-CORE(SM) registry","volume":"32","author":"Gonzalez-Ruiz","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.bjid.2019.05.006_bib0070","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jac\/dkt067","article-title":"Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database","volume":"68","author":"Seaton","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1471-2334-12-133","article-title":"Daptomycin therapy for osteomyelitis: a retrospective study","volume":"12","author":"Gallagher","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0080","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jac\/dkq528","article-title":"Clinical experience with daptomycin in Europe: the first 2.5 years","volume":"66","author":"Gonzalez-Ruiz","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1179\/joc.2009.21.4.414","article-title":"Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE registry","volume":"21","author":"Crompton","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1345\/aph.1K535","article-title":"Clinical experience with daptomycin for the treatment of patients with documented Gram-positive septic arthritis","volume":"42","author":"Forrest","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0095","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.amjmed.2007.07.010","article-title":"Clinical experience with daptomycin for the treatment of patients with osteomyelitis","volume":"120","author":"Lamp","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.bjid.2019.05.006_bib0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/BLO.0b013e3181123bc5","article-title":"Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study","volume":"461","author":"Holtom","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.bjid.2019.05.006_bib0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dkm437","article-title":"Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia","volume":"61","author":"Lalani","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0110","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1128\/AAC.00038-12","article-title":"Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty","volume":"56","author":"Byren","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0115","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1185\/030079905X74961","article-title":"Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections","volume":"21","author":"Finney","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bjid.2019.05.006_bib0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.blo.0000224021.73163.61","article-title":"Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series","volume":"451","author":"Rao","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.bjid.2019.05.006_bib0125","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.clinthera.2012.06.013","article-title":"Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study","volume":"34","author":"Moenster","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.bjid.2019.05.006_bib0130","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dks119","article-title":"Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections","volume":"67","author":"Corona Perez-Cardona","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.diagmicrobio.2014.05.022","article-title":"High doses of daptomycin (10\u202fmg\/kg\/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study","volume":"80","author":"Lora-Tamayo","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.medcli.2017.04.031","article-title":"High-dose daptomycin together with rifampin as salvage therapy for prosthetic joint infections","volume":"149","author":"Herrera","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.bjid.2019.05.006_bib0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jmii.2011.09.018","article-title":"Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections","volume":"45","author":"Lai","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.bjid.2019.05.006_bib0150","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1186\/s12879-017-2842-6","article-title":"Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection","volume":"17","author":"Chang","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12879-016-1366-9","article-title":"Methicillin-resistant Staphylococcal periprosthetic joint infections can be effectively controlled by systemic and local daptomycin","volume":"16","author":"Kuo","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0160","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00264-013-1856-y","article-title":"The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections","volume":"37","author":"Jugun","year":"2013","journal-title":"Int Orthop"},{"key":"10.1016\/j.bjid.2019.05.006_bib0165","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10096-013-2001-y","article-title":"Daptomycin versus vancomycin for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA): a nested case-control study","volume":"33","author":"Liang","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12879-016-1420-7","article-title":"Daptomycin & 6\u202fmg\/kg\/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center","volume":"16","author":"Roux","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2019.05.006_bib0175","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1128\/AAC.02344-14","article-title":"Penetration of daptomycin into bone and synovial fluid in joint replacement","volume":"58","author":"Montange","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0180","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/jac\/dkq109","article-title":"Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections","volume":"65","author":"Traunmuller","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0185","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.02597-15","article-title":"Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections","volume":"60","author":"Goutelle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jor.20003","article-title":"Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis","volume":"24","author":"Ellington","year":"2006","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bjid.2019.05.006_bib0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S8756-3282(99)00239-2","article-title":"In vivo internalization of Staphylococcus aureus by embryonic chick osteoblasts","volume":"26","author":"Reilly","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bjid.2019.05.006_bib0200","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2106\/00004623-200506000-00022","article-title":"Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report","volume":"87","author":"Bosse","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.bjid.2019.05.006_bib0205","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.04359-14","article-title":"Antimicrobial activity against intraosteoblastic Staphylococcus aureus","volume":"59","author":"Valour","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0210","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/jac\/dkx314","article-title":"Intraosteoblastic activity of daptomycin in combination with oxacillin and ceftaroline against MSSA and MRSA","volume":"72","author":"Dupieux","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0215","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.amjsurg.2006.04.009","article-title":"Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices","volume":"192","author":"Edmiston","year":"2006","journal-title":"Am J Surg"},{"key":"10.1016\/j.bjid.2019.05.006_bib0220","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s15010-016-0874-2","article-title":"Should daptomycin-rifampin combinations for MSSA\/MRSA isolates be avoided because of antagonism?","volume":"44","author":"Stein","year":"2016","journal-title":"Infection"},{"key":"10.1016\/j.bjid.2019.05.006_bib0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2015.04.004","article-title":"Daptomycin combinations as alternative therapies in experimental foreign-body infection caused by meticillin-susceptible Staphylococcus aureus","volume":"46","author":"El Haj","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2019.05.006_bib0230","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijantimicag.2013.02.018","article-title":"In vitro susceptibility to antibiotics of staphylococci in biofilms isolated from orthopaedic infections","volume":"41","author":"Molina-Manso","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2019.05.006_bib0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01232226","article-title":"Release of gentamicin from polymethyl methacrylate. I. Experimental in-vitro tests","volume":"331","author":"Wahlig","year":"1972","journal-title":"Langenbecks Arch Chir"},{"key":"10.1016\/j.bjid.2019.05.006_bib0240","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jac\/dkh032","article-title":"Release of gentamicin and vancomycin from temporary human hip spacers in two-stage revision of infected arthroplasty","volume":"53","author":"Bertazzoni Minelli","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2019.05.006_bib0245","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.arth.2018.01.056","article-title":"Changes in antibiotic susceptibility of Staphylococcus aureus between the stages of 2-stage revision arthroplasty","volume":"33","author":"George","year":"2018","journal-title":"J Arthroplasty"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867019301023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867019301023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:54:01Z","timestamp":1761407641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867019301023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1413867019301023"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2019.05.006","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}